Harbour BioMed

Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020

by

HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally. HBM1020 was generated from Harbour Mice® H2L2 transgenic mice platform. HBM1020 has great potential to address huge unmet medical needs in patients with advanced malignancies. CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 4, 2023 /PRNewswire/ — Harbour BioMed (HKEX: 02142) announced … Read more

Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

by

Porustobart in combination of toripalimab showed promising anti-tumor activity Porustobart in combination of toripalimab showed acceptable safety profile in HCC Porustobart in combination of toripalimab showed favorable PK/PD signature CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, May 28, 2023 /PRNewswire/ — Harbour BioMed (the “Company”, HKEX: 02142), a global biopharmaceutical company committed to the discovery, … Read more